Reference  is made to the stock exchange  notice from Hofseth BioCare ASA ("HBC"
or the "Company") published on 3 July 2022 regarding the completion of a private
placement  raising  gross  proceeds  of  approximately  NOK  141 million through
issuance  of new shares in the Company,  and the primary insider notification on
3 July 2022 regarding, inter alia, a share lending agreement between the Company
and  Ødegård  Prosjekt  AS  (a  close  associate  of  CFO Jon Olav Ødegård). All
958,810 shares  lent out from  Ødegård Prosjekt AS  have now been redelivered to
Ødegård Prosjekt AS.

Further information about the transaction is set out in the attached form.

For further information, please contact:

Jon Olav Ødegård, CFO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

This information is subject to the disclosure requirements pursuant to
Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act
section 5-12.